Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $12.92, but opened at $12.0460. Santen Pharmaceutical shares last traded at $12.0460, with a volume of 146 shares traded.
Wall Street Analyst Weigh In
Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold”.
Check Out Our Latest Stock Report on Santen Pharmaceutical
Santen Pharmaceutical Price Performance
About Santen Pharmaceutical
Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.
Featured Articles
- Five stocks we like better than Santen Pharmaceutical
- Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build
- 2 ETFs to Access the World’s Best-Performing Stock Markets In 2026
- IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story
- Alphabet Is Planning a New AI Chip. Here’s Why It Matters Ahead of Earnings
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
